SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) rose 2.3% on Monday . The company traded as high as $10.93 and last traded at $10.80, with a volume of 226,962 shares trading hands. The stock had previously closed at $10.56.

The stock has a market capitalization of $535.52 million and a price-to-earnings ratio of 19.87. The firm’s 50 day moving average price is $12.50 and its 200 day moving average price is $11.40.

SciClone Pharmaceuticals (NASDAQ:SCLN) last released its quarterly earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported $0.19 earnings per share for the quarter. The firm earned $36.50 million during the quarter, compared to analyst estimates of $33.60 million. Equities analysts predict that SciClone Pharmaceuticals Inc. will post $0.33 EPS for the current fiscal year.

A hedge fund recently raised its stake in SciClone Pharmaceuticals stock. Cornerstone Capital Management Holdings LLC. boosted its position in SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) by 32.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 198,570 shares of the specialty pharmaceutical company’s stock after buying an additional 48,470 shares during the period. Cornerstone Capital Management Holdings LLC. owned approximately 0.40% of SciClone Pharmaceuticals worth $1,827,000 as of its most recent filing with the SEC.

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.